Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva’s anti-IL-15 candidate, TEV-‘408 ...
Email scams are targeting seniors at alarming rates, threatening life savings with a single click. Discover how families can ...
Category-Level Shrink Insights is compatible with Sensormatic Solutions award-winning source-tagging service, giving ...
Partnership adds engineering and guidance to accelerate Bridge's AI development, and application of Ferguson's patented ...
Trump’s Venezuela oil grab, Rio Tinto-Glencore talks and ex-TD banker pleads guilty to money laundering: Business and ...
Writing in a note, the Barclays analysts including Alejandro Arreaza and Jason Keene argued that if the U.S. incursion lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback